225 related articles for article (PubMed ID: 21048203)
1. Companies look for profit in orphan drugs.
Thompson CA
Am J Health Syst Pharm; 2010 Nov; 67(22):1892, 1895-6. PubMed ID: 21048203
[No Abstract] [Full Text] [Related]
2. [Conference 1. An economic observatory for orphan drugs: myth or reality?].
Duguet C; Ferry A
Med Sci (Paris); 2014 Apr; 30 Spe(1):21-3. PubMed ID: 24755173
[No Abstract] [Full Text] [Related]
3. Medicines for rare (orphan) diseases: an enquiry and proposal for tax-incentives.
John JE
Drug Discov Today; 2011 Dec; 16(23-24):999-1000. PubMed ID: 22020052
[No Abstract] [Full Text] [Related]
4. The European rare diseases therapeutic initiative.
Fischer A; Borensztein P; Roussel C
PLoS Med; 2005 Sep; 2(9):e243. PubMed ID: 16104832
[TBL] [Abstract][Full Text] [Related]
5. New drugs carry hefty price tags. Makers of leading-edge orphan products asked to cut prices, take smaller profits.
Lee J
Mod Healthc; 2013 Oct; 43(40):14. PubMed ID: 24340725
[No Abstract] [Full Text] [Related]
6. Birgitte Volck.
Nat Rev Drug Discov; 2017 May; 16(6):378-379. PubMed ID: 28559559
[No Abstract] [Full Text] [Related]
7. [European incentives for orphan medicinal products].
Enzmann H; Lütz J
Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2008 May; 51(5):500-8. PubMed ID: 18696141
[TBL] [Abstract][Full Text] [Related]
8. Regulators adopt more orphan drugs.
Reardon S
Nature; 2014 Apr; 508(7494):16-7. PubMed ID: 24695293
[No Abstract] [Full Text] [Related]
9. Lucrative niches: how drugs for rare diseases became lifeline for companies.
Anand G
Wall St J (East Ed); 2005 Nov; ():A1, A18. PubMed ID: 16502531
[No Abstract] [Full Text] [Related]
10. Rare diseases and effective treatments: are we delivering?
Luzzatto L; Hollak CE; Cox TM; Schieppati A; Licht C; Kääriäinen H; Merlini G; Schaefer F; Simoens S; Pani L; Garattini S; Remuzzi G
Lancet; 2015 Feb; 385(9970):750-2. PubMed ID: 25752159
[No Abstract] [Full Text] [Related]
11. Pfizer explores rare disease path.
Shaffer C
Nat Biotechnol; 2010 Sep; 28(9):881-2. PubMed ID: 20829809
[No Abstract] [Full Text] [Related]
12. [Cohorts and registers: Which public/private partnerships to choose?].
Jouan-Flahault C; Landais P; Thomas R; Parker S; Genevaz D
Presse Med; 2012 May; 41 Suppl 1():S15-9. PubMed ID: 22464892
[No Abstract] [Full Text] [Related]
13. [Orphan drugs--medications for patients with rare diseases].
Thielke D; Thyssen JP; Hansen BJ
Ugeskr Laeger; 2006 Jun; 168(23):2236-8. PubMed ID: 16768975
[TBL] [Abstract][Full Text] [Related]
14. Do investors value the FDA orphan drug designation?
Miller KL
Orphanet J Rare Dis; 2017 Jun; 12(1):114. PubMed ID: 28629392
[TBL] [Abstract][Full Text] [Related]
15. Proposed 'grant-and-access' program with price caps could stimulate development of drugs for very rare diseases.
Valverde AM; Reed SD; Schulman KA
Health Aff (Millwood); 2012 Nov; 31(11):2528-35. PubMed ID: 23129684
[TBL] [Abstract][Full Text] [Related]
16. Competing for public funding of medicines to treat rare disorders in New Zealand.
Crausaz S
Bull World Health Organ; 2015 Feb; 93(2):67. PubMed ID: 25883396
[No Abstract] [Full Text] [Related]
17. Big pharma moves from 'blockbusters' to 'niche busters'.
Dolgin E
Nat Med; 2010 Aug; 16(8):837. PubMed ID: 20689537
[No Abstract] [Full Text] [Related]
18. The challenges of orphan drugs and orphan diseases: real and imagined.
Hudson I; Breckenridge A
Clin Pharmacol Ther; 2012 Aug; 92(2):151-3. PubMed ID: 22814659
[TBL] [Abstract][Full Text] [Related]
19. Jumpstarting research into neglected diseases.
Leslie M
Cell; 2006 Nov; 127(3):443-5. PubMed ID: 17081963
[TBL] [Abstract][Full Text] [Related]
20. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
Liu BC; He L; He G; He Y
J Public Health Policy; 2010 Dec; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]